AB Science Corporate Presentation
AB Science Corporate Presentation
AB Science Corporate Presentation
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA